{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T23:09:06Z","timestamp":1795216146883,"version":"4.10.3"},"reference-count":50,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,4,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite recent advances, allografting remains the only potential cure for myeloma. From July 1999 to June 2005, 100 newly diagnosed patients younger than 65 years were enrolled in a prospective multicenter study. First-line treatment included vincristin, adriamycin, and dexamethasone (VAD)\u2013based induction chemotherapy, a cytoreductive autograft (melphalan 200 mg\/m2) followed by a single dose of nonmyeloablative total body irradiation and allografting from an human leukocyte antigen (HLA)\u2013identical sibling. Primary end points were the overall survival (OS) and event-free survival (EFS) from diagnosis. After a median follow-up of 5 years, OS was not reached, and EFS was 37 months. Incidences of acute and chronic graft-versus-host disease (GVHD) were 38% and 50%, respectively. Complete remission (CR) was achieved in 53% of patients. Profound cytoreduction (CR or very good partial remission) before allografting was associated with achievement of posttransplantation CR (hazard ratio [HR] 2.20, P = .03) and longer EFS (HR 0.33, P &lt; .01). Conversely, development of chronic GVHD was not correlated with CR or response duration. This tandem transplantation approach allows prolonged survival and long-term disease control in patients with reduced tumor burden at the time of allografting. We are currently investigating the role of \u201cnew drugs\u201d in intensifying pretransplantation cytoreduction and posttransplantation graft-versus-myeloma effects to further improve clinical outcomes. (http:\/\/ClinicalTrials.gov; NCT-00702247.)<\/jats:p>","DOI":"10.1182\/blood-2008-07-167379","type":"journal-article","created":{"date-parts":[[2008,12,9]],"date-time":"2008-12-09T01:59:27Z","timestamp":1228787967000},"page":"3375-3382","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":78,"title":["Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo"],"prefix":"10.1182","volume":"113","author":[{"given":"Benedetto","family":"Bruno","sequence":"first","affiliation":[{"name":"Division of Hematology, S Giovanni Battista Hospital, University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Rotta","sequence":"additional","affiliation":[{"name":"Division of Hematology, S Giovanni Battista Hospital, University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Patriarca","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Clinical and Morphological Researches, University of Udine, Udine, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Mattei","sequence":"additional","affiliation":[{"name":"Division of Hematology, S Croce e Carle Hospital, Cuneo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardino","family":"Allione","sequence":"additional","affiliation":[{"name":"Division of Hematology, SS Antonio e Biagio Hospital, Alessandria, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Carnevale-Schianca","sequence":"additional","affiliation":[{"name":"Division of Oncology, Institute for Cancer Research and Treatment (IRCC), Candiolo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Sorasio","sequence":"additional","affiliation":[{"name":"Division of Hematology, S Giovanni Battista Hospital, University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Ospedali Riuniti, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Casini","sequence":"additional","affiliation":[{"name":"Division of Hematology, Regional Hospital, Bolzano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Parma","sequence":"additional","affiliation":[{"name":"Division of Hematology, S Gerardo Hospital, University of Milano, Bicocca, Monza, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasqua","family":"Bavaro","sequence":"additional","affiliation":[{"name":"Division of Hematology, Ospedale Civile, Pescara, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Onida","sequence":"additional","affiliation":[{"name":"Division of Hematology at the Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Busca","sequence":"additional","affiliation":[{"name":"Division of Hematology, S Giovanni Battista Hospital, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Castagna","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Benedetti","sequence":"additional","affiliation":[{"name":"Division of Hematology, S Chiara Hospital, University of Pisa, Pisa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Paola","family":"Iori","sequence":"additional","affiliation":[{"name":"Division of Hematology, University La Sapienza, Roma, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Giaccone","sequence":"additional","affiliation":[{"name":"Division of Hematology, S Giovanni Battista Hospital, University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Division of Hematology, S Giovanni Battista Hospital, University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[{"name":"Division of Hematology, Istituto Nazionale Tumori, University of Milano, Milano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Fanin","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Clinical and Morphological Researches, University of Udine, Udine, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Maloney","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, University of Washington, Seattle;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Storb","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, University of Washington, Seattle;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana","family":"Baldi","sequence":"additional","affiliation":[{"name":"Unit\u00e0 di Epidemiologia dei Tumori, S G B Hospital and CPO, Piemonte, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Ricardi","sequence":"additional","affiliation":[{"name":"Radiation Oncology Unit, S Giovanni Battista Hospital, University of Torino, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[{"name":"Division of Hematology, S Giovanni Battista Hospital, University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111713080519500_B1","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma.","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"2019111713080519500_B2","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0140-6736(05)64525-4","article-title":"Graft-versus-myeloma effect.","volume":"348","author":"Aschan","year":"1996","journal-title":"Lancet"},{"key":"2019111713080519500_B3","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: proof of principle.","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"key":"2019111713080519500_B4","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.bmt.1703253","article-title":"Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect.","volume":"28","author":"Le Blanc","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"2019111713080519500_B5","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111713080519500_B6","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/blood.V88.7.2787.bloodjournal8872787","article-title":"Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome.","volume":"88","author":"Bensinger","year":"1996","journal-title":"Blood"},{"key":"2019111713080519500_B7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1365-2141.2001.02726.x","article-title":"Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres.","volume":"113","author":"Gahrton","year":"2001","journal-title":"Br J Haematol"},{"key":"2019111713080519500_B8","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2002-01-0131","article-title":"Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma.","volume":"100","author":"Kroger","year":"2002","journal-title":"Blood"},{"key":"2019111713080519500_B9","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","article-title":"Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.","volume":"102","author":"Maloney","year":"2003","journal-title":"Blood"},{"key":"2019111713080519500_B10","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A comparison of allografting with autografting for newly-diagnosed myeloma.","volume":"356","author":"Bruno","year":"2007","journal-title":"N Engl J Med"},{"key":"2019111713080519500_B11","article-title":"Reduced intensity conditioning regimen for allografting following autografting has strong anti-myeloma activity and delays disease progression compared to tandem autografting.","volume":"108","author":"Carella","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"2019111713080519500_B12","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","article-title":"A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma.","volume":"112","author":"Rosinol","year":"2008","journal-title":"Blood"},{"key":"2019111713080519500_B13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cancergencyto.2005.10.016","article-title":"Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance.","volume":"167","author":"Schmidt-Wolf","year":"2006","journal-title":"Cancer Genet Cytogenet"},{"key":"2019111713080519500_B14","first-page":"825","article-title":"Consensus conference on acute GVHD grading.","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"2019111713080519500_B15","first-page":"250","article-title":"Chronic graft-versus-host disease and other late complications of bone marrow transplantation.","volume":"28","author":"Sullivan","year":"1991","journal-title":"Semin Hematol"},{"key":"2019111713080519500_B16","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma.","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"2019111713080519500_B17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2019111713080519500_B18","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1002\/1097-0258(20001115)19:21<3005::AID-SIM592>3.0.CO;2-9","article-title":"Estimation of current leukaemia-free survival following donor lymphocyte infusion therapy for patients with leukaemia who relapse after allografting: application of a multistate model.","volume":"19","author":"Klein","year":"2000","journal-title":"Stat Med"},{"key":"2019111713080519500_B19","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"2019111713080519500_B20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables (with discussion).","volume":"24","author":"Cox","year":"1972","journal-title":"J R Statist Soc"},{"key":"2019111713080519500_B21","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/01621459.1989.10478873","article-title":"Regression analysis of multivariate incomplete failure time data by modeling marginal distributions.","volume":"84","author":"Wei","year":"1989","journal-title":"J Am Stat Assoc"},{"key":"2019111713080519500_B22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-94-015-7983-4_14","article-title":"Cox-type regression analysis for large number of small groups of correlated failure time observations.","volume-title":"Survival Analysis: State of the Art","author":"Lee","year":"1992"},{"key":"2019111713080519500_B23","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1002\/sim.4780132105","article-title":"Cox regression analysis of multivariate failure time data: the marginal approach.","volume":"13","author":"Lin","year":"1994","journal-title":"Stat Med"},{"key":"2019111713080519500_B24","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazard tests and diagnostics based on weighted residuals.","volume":"81","author":"Grambsh","year":"1994","journal-title":"Biometrika"},{"key":"2019111713080519500_B25","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3462-1","volume-title":"Regression Modeling Strategies","author":"Harrell","year":"2001"},{"key":"2019111713080519500_B26","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma.","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111713080519500_B27","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111713080519500_B28","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma.","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111713080519500_B29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2006.06271.x","article-title":"Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.","volume":"135","author":"Barlogie","year":"2006","journal-title":"Br J Haematol"},{"key":"2019111713080519500_B30","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"2019111713080519500_B31","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"2019111713080519500_B32","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"2019111713080519500_B33","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.1999.17.1.208","article-title":"Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells.","volume":"17","author":"Corradini","year":"1999","journal-title":"J Clin Oncol"},{"key":"2019111713080519500_B34","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2003-01-0189","article-title":"Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.","volume":"102","author":"Corradini","year":"2003","journal-title":"Blood"},{"key":"2019111713080519500_B35","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2008-03-145235","article-title":"Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"key":"2019111713080519500_B36","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1200\/JCO.2007.11.7879","article-title":"Relationship between depth of response and outcome in multiple myeloma.","volume":"25","author":"Dingli","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111713080519500_B37","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.exphem.2006.02.020","article-title":"Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.","volume":"34","author":"Kroger","year":"2006","journal-title":"Exp Hematol"},{"key":"2019111713080519500_B38","first-page":"837","article-title":"Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.","volume":"91","author":"Bruno","year":"2006","journal-title":"Haematologica"},{"key":"2019111713080519500_B39","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1182\/blood-2005-11-4449","article-title":"Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.","volume":"107","author":"van de Donk","year":"2006","journal-title":"Blood"},{"key":"2019111713080519500_B40","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2007.15.2546","article-title":"Individualizing treatment of patients with myeloma in the era of novel agents.","volume":"26","author":"San-Miguel","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019111713080519500_B41","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa050642","article-title":"Protective conditioning for acute graft-versus-host disease.","volume":"353","author":"Lowsky","year":"2005","journal-title":"N Engl J Med"},{"key":"2019111713080519500_B42","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.beha.2006.06.002","article-title":"The immune system as a foundation for immunologic therapy and hematologic malignancies: a historical perspective.","volume":"19","author":"Baron","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"2019111713080519500_B43","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.leu.2403718","article-title":"High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation.","volume":"19","author":"Baron","year":"2005","journal-title":"Leukemia"},{"key":"2019111713080519500_B44","article-title":"Higher doses of transplanted T and B cells are associated with greater incidence of extensive chronic GVHD after PBSC transplantation from HLA-identical sibling donors.","volume":"110","author":"Baron","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"2019111713080519500_B45","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome.","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"key":"2019111713080519500_B46","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"key":"2019111713080519500_B47","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/leu.2008.88","article-title":"Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.","volume":"22","author":"Schilling","year":"2008","journal-title":"Leukemia"},{"key":"2019111713080519500_B48","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bmt.1705810","article-title":"The allogeneic dilemma.","volume":"40","author":"Harousseau","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"2019111713080519500_B49","article-title":"Limited graft versus myeloma effect after low-dose TBI based non-myeloablative allografting employed as salvage treatment compared to first line treatment.","volume":"37","author":"Giaccone","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"2019111713080519500_B50","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.4049\/jimmunol.176.11.6935","article-title":"Identification of HLA-A*0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies.","volume":"176","author":"Siegel","year":"2006","journal-title":"J Immunol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/14\/3375\/1306053\/zh801409003375.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/14\/3375\/1306053\/zh801409003375.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T02:31:34Z","timestamp":1738809094000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/113\/14\/3375\/24832\/Nonmyeloablative-allografting-for-newly-diagnosed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,2]]},"references-count":50,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2009,4,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2008-07-167379","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,2]]}}}